![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, March 14, 2023 10:45:48 AM
MARCH 14, 20237:25 AM UPDATED AN HOUR AGO
Trial data supports Pfizer's COVID drug for high-risk adults -FDA staff
By Reuters Staff
March 14 (Reuters) - Trial results for Pfizer Inc’s antiviral pill, Paxlovid, supported its use to treat mild-to-moderate COVID-19 in adults at high-risk of severe disease, staff reviewers at the Food and Drug Administration said on Tuesday.
The comments were made in the regulator’s briefing documents ahead of a meeting of the FDA’s external advisers on Thursday to discuss a possible full approval for Pfizer’s oral pill, which has been cleared for emergency use since late 2021."
https://www.reuters.com/article/health-coronavirus-pfizer-fda/trial-data-supports-pfizers-covid-drug-for-high-risk-adults-fda-staff-idUSL4N35M387
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM